Quick answer: whoever wrote the formula owns it, unless a contract says otherwise. In OEM the brand brings the formula and keeps it; in ODM the factory's library formula stays the factory's, and you get a licence to sell it — sometimes exclusive, usually not. The ownership test is not the invoice: it is whether you hold a formula specification with quantitative levels, a batch record you are allowed to audit, and a written assignment or licence. No paperwork, no ownership.
By Jack Liu, Export Manager, ZOOMSHEAL · Reviewed by the ZOOMSHEAL quality and regulatory team · Last updated 8 November 2026
1. The four arrangements you will actually be offered
| Model | Who writes the formula | Who owns it | Who can sell it |
|---|---|---|---|
| OEM / contract manufacturing | You (or your formulator) | You | Only you |
| ODM — factory library formula | Factory R&D | Factory | Anyone the factory licenses; you, unless exclusivity is bought |
| White label | Factory | Factory | Many brands, identical product, different label |
| Exclusive licence / private formula | Factory, developed for you | Factory, with an exclusive licence to you | Only you, for a defined term and territory |
The distinction that matters commercially is not OEM versus ODM, it is exclusive versus non-exclusive. A non-exclusive ODM formula means the product on your shelf can appear on a competitor's shelf next quarter with a different label. For commodity formats that is fine. For a brand you intend to build, it is the whole ballgame.
2. What "owning" a formula legally involves
A supplement formula is rarely patented — most are not novel enough, and publication is usually undesirable. Ownership is therefore built from three thinner but workable rights:
- Trade secret. The quantitative formula, the grade of each ingredient, the process parameters and the supplier list are confidential information. Protection depends on documented confidentiality, access control, and an actual clause — not on registration.
- Copyright in the written specification. The formula sheet, the master batch record and the artwork are documents; copyright in them can be assigned.
- Contract. The assignment or licence clause is the enforceable instrument. It is what a court reads when the relationship ends.
So the practical question is not "who invented it" but "what does the paper say, and can I prove the paper describes the product I am selling".
3. The five clauses that decide ownership
| Clause | What it must say | What happens without it |
|---|---|---|
| IP assignment | All rights in the formula, specification and batch record vest in the brand | Factory keeps the formula and can reuse it |
| Confidentiality | Survives termination, 5+ years, covers suppliers and levels | Formula is not protected as a trade secret |
| Exclusivity | Named territory, term, and what counts as a competing product | Same formula sold to your competitor |
| Tooling | Who owns moulds, dies and plates, and where they are stored | Tooling stranded at the factory |
| Transition | Obligation to hand over the specification and a batch record on exit | You cannot move to a second source |
Notice that three of the five are about what happens when the relationship ends. That is not pessimism; it is where the money is.
4. ODM in China: what you are really buying
Most Chinese factories hold a library of proven formulas — magnesium blends, gummy multivitamins, sleep powders, joint complexes — developed over years and amortised across many customers. Buying one of those is fast and cheap: no development fee, existing stability data, known process parameters, and a MOQ that is often lower than a bespoke formula.
What you buy is a licence, not an asset. Expect three variations:
- Non-exclusive, no fee. Lowest cost, no protection. You are one of many labels on the same fill.
- Category exclusivity. The factory will not sell that formula to another brand in your market for a term — typically priced as a premium per unit or an annual fee.
- Formula purchase or assignment. Rarer, priced as a development fee, and worth it only when the formula is genuinely differentiating.
Ask which one the quote assumes. The word "custom" appears in every brochure; exclusivity appears only in contracts.
5. Red flags in formula conversations
- "The formula is free" — it is free because you do not own it.
- No quantitative levels in the specification, only a list of ingredients. If you cannot see mg per serving, you cannot own or defend the formula.
- Refusal to name the ingredient grade (e.g. magnesium bisglycinate versus magnesium oxide at the same elemental weight). Grade is most of the cost and all of the performance.
- No NDI or novel food assessment offered for a new ingredient — ownership without regulatory clearance is a liability, not an asset.
- Tooling described as "ours" with no address, no inventory list, no transfer clause.
- Batch record access refused "for confidentiality" — that is a supplier telling you it does not want an audit trail between your formula and its process.
6. What to demand so ownership is provable
- Formula specification with quantitative levels per serving, ingredient grade, overage, and excipients, signed and dated.
- Master batch record reference, plus the right to inspect a redacted copy.
- Written assignment or licence naming the territory, term, and exclusivity scope.
- Supplier list under NDA — at minimum, the active ingredient sources, so a second manufacturer can match them.
- Stability and release data that belong to your product, not a generic file.
- Regulatory file: NDI notification, novel food status, allergen and GMO statements.
If you hold all six, switching manufacturers is a project. If you hold none, switching is a restart.
7. Cost and speed comparison
| Your own formula (OEM) | Factory library (ODM) | |
|---|---|---|
| Development time | 4–10 weeks plus stability | 0 — already validated |
| Development cost | USD 1,500–8,000 depending on complexity | Usually none |
| Minimum order | Often higher on a first run | Frequently lower |
| Differentiation | High | Low unless exclusivity is bought |
| Switching cost later | Moderate — you own the spec | High — you may not have the spec |
| Regulatory burden | Yours (NDI, claims) | Yours, but the file often exists |
9. The exit playbook: moving a formula to a second manufacturer
Ownership is tested when you leave. A transfer takes 4–8 weeks if you hold the documents, and it becomes a redevelopment project if you do not. The sequence below is the one that keeps the product identical.
| Step | Deliverable | Time | Blocker if missing |
|---|---|---|---|
| 1. Formula specification | Quantitative levels, grades, overage, excipients | Week 1 | New lab must redevelop, 4–10 weeks |
| 2. Raw material sources | Named suppliers and grades for actives | Week 1–2 | Substitution changes assay and taste |
| 3. Process parameters | Temperatures, times, sieve sizes, compression force | Week 2 | Trials and yield loss |
| 4. Reference samples | Two retained units from the last approved batch | Week 2 | No sensory or dissolution benchmark |
| 5. Artwork files | Print-ready separations, dielines, colour proofs | Week 2 | Redesign and re-proof |
| 6. Tooling transfer | Moulds, dies, plates, with inventory photos | Week 3–4 | New tooling cost and lead time |
| 7. Validation batch | Pilot at the new site, tested against spec | Week 4–6 | Cannot confirm equivalence |
Step 4 is the one buyers forget. Without a retained sample of the approved product, the new manufacturer can match the paperwork and still deliver a different mouthfeel, colour or dissolution profile — and you will have no benchmark to argue with.
10. How to write the ownership clause so it survives a dispute
Three sentences do most of the work, and they should appear in the manufacturing agreement, not in an email: the brand owns all intellectual property in the formula, specification, master batch record and artwork, including copyright and trade secrets, with rights vesting on payment; the manufacturer will not use, sell or disclose the formula or any derivative to a third party without written consent; and on termination the manufacturer will deliver the specification, batch record extract, supplier list and artwork files within 15 business days.
Add two protections that cost nothing at signature and a great deal later: a schedule listing the deliverables that constitute the formula, and a clause stating that a failure to deliver them is a material breach with a defined remedy. Without a schedule, "the formula" is whatever the factory says it is.
Frequently asked questions
If I pay for the development, do I own the formula?
Only if the contract assigns it. Paying a development fee buys work, not rights. The clause should say the rights vest in you on payment, and should list the deliverables that constitute the formula.
Can two brands sell the same ODM formula legally?
Yes, and it happens constantly. Nothing prevents it unless exclusivity was purchased. It is legal, common, and usually invisible to consumers until the labels are compared side by side.
How much does exclusivity cost?
Commonly a per-unit premium of 5–15%, or a fixed annual fee, or a minimum volume commitment. Anything marketed as free exclusivity is usually limited to a category the factory does not sell much of anyway.
Does owning the formula let me change manufacturers?
Only if you also hold the specification, the batch record reference, the supplier list and the stability data. Ownership without documentation is a claim you cannot operationalise.
Who owns the label artwork and the brand?
You should, and the contract should say so explicitly, including the separations and the print-ready files. Factories routinely retain artwork files, which becomes leverage at the worst possible moment.
What about the moulds and dies I paid for?
They are yours if the contract says so, and you should record an inventory with photographs and serial numbers. Otherwise you paid for tooling that stays on someone else's floor.
Sources
- US FDA, 21 CFR Part 111 — batch production records and reserve samples. ecfr.gov
- US FDA, New Dietary Ingredient Notifications. fda.gov
- WIPO, Trade Secrets and Confidential Information. wipo.int
- USP <2232> Elemental Contaminants in Dietary Supplements. usp.org
- European Commission, Directive 2002/46/EC on food supplements. eur-lex.europa.eu
- Regulation (EC) No 1924/2006 on nutrition and health claims. eur-lex.europa.eu
About this guide
Based on formula assignment and transition work for private label brands moving between suppliers, and on the specification set we hand over when a brand exits. This is commercial guidance, not legal advice; have the assignment clause reviewed by counsel in your market. Last substantive revision: 8 November 2026.
